S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3‐mediated programmed death‐ligand 1 expression in colorectal cancer

Min, Hye‐Young; Cho, Jaebeom; Sim, Jeong Yeon; Boo, Hye‐Jin; Lee, Ji‐Sun; Lee, Seon‐Boon; Lee, None Young‐Jin; Kim, Sung Joo; Kim, Kyu‐Pyo; Park, In‐Ja; Hong, Seung‐Mo; Zhang, Xueli; Zhang, Z.; Park, Rang‐Woon; Lee, Ho‐Young

doi:10.1002/ctm2.986

Cited by 12 publications

(6 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have declared that other potential biomarkers are related to the immunoevasive microenvironment of CRC. Lee et al [ 60 ] identified that S100A14 inhibits STAT3-mediated PD-1 expression and the phenotype of tumor stem cells, promotes CD8 + T-cell-mediated cytotoxicity, inhibits immune evasion, and restores chemosensitivity. Thus, targeting S100A14 is likely an effective strategy for preventing CRC progression, and S100A14 could be regarded as a promising indicator for anti-PD-L1 immunotherapy and chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation

Weng,

Lai,

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation

Weng,

Lai,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…In addition, it is noteworthy that some of these 29 specific single-cell marker genes have been studied in tumor immunotherapy( Macor et al, 2015 ; Strati et al, 2017 ; Shen et al, 2021 ; Ahmed et al, 2022 ; Min et al, 2022 ), but their role in the response of CRC to immunotherapy is still unclear. Combined with the results of CellMiner, it is suggested that these genes may be potential synergistic targets for enhancing the sensitivity of immunotherapy in CRC patients.…”

Section: Discussionmentioning

confidence: 99%

Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy

Jin²,

Chen³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Mismatch repair-proficient (pMMR) microsatellite stability (MSS) in colorectal cancer (CRC) indicates an unfavorable therapeutic response to immunotherapy with immune checkpoint inhibitors (ICIs). However, the molecular characteristics of CRC patients with pMMR MSS remain largely unknown.Methods: Heterogeneities between mismatch repair-deficient (dMMR) microsatellite instability (MSI) and pMMR MSS CRC patients were investigated at the single-cell level. Next, an MSS-related risk score was constructed by single-sample gene set enrichment analysis (ssGSEA). The differences in immune and functional characteristics between the high- and low-score groups were systematically analyzed.Results: Based on the single-cell RNA (scRNA) atlas, an MSS-specific cancer cell subpopulation was identified. By taking the intersection of the significant differentially expressed genes (DEGs) between different cancer cell subtypes of the single-cell training and validation cohorts, 29 MSS-specific cancer cell marker genes were screened out for the construction of the MSS-related risk score. This risk score signature could efficiently separate pMMR MSS CRC patients into two subtypes with significantly different immune characteristics. The interactions among the different cell types were stronger in the MSS group than in the MSI group, especially for the outgoing signals of the cancer cells. In addition, functional differences between the high- and low-score groups were preliminarily investigated.Conclusion: In this study, we constructed an effective risk model to classify pMMR MSS CRC patients into two completely different groups based on the specific genes identified by single-cell analysis to identify potential CRC patients sensitive to immunotherapy and screen effective synergistic targets.

show abstract

“…EMT induced PD-L1 expressed on CSCs via EMT/b-catenin/STT3/PD-L1 signaling axis, and targeting EMT/b-catenin/STT3/PD-L1 axis may downregulate PD-L1 (40). In colorectal cancer, PD-L1 can trigger CSC-like characteristics and chemoresistance in CRC cells (41). PD-L1 overexpressed on CD133 + colorectal CSCs and EMT enable CSCs to invade and metastasize (37).…”

Section: Elevated Expression Of Immune Checkpoint Moleculesmentioning

confidence: 99%

Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

Liu

2023

Front. Oncol.

View full text Add to dashboard Cite

As a relatively rare population of cancer cells existing in the tumor microenvironment, cancer stem cells (CSCs) possess properties of immune privilege to evade the attack of immune system, regulated by the microenvironment of CSCs, the so-called CSCs niche. The bidirectional interaction of CSCs with tumor microenvironment (TME) components favors an immunosuppressive shelter for CSCs’ survival and maintenance. Gastrointestinal cancer stem cells (GCSCs) are broadly regarded to be intimately involved in tumor initiation, progression, metastasis and recurrence, with elevated tumor resistance to conventional therapies, which pose a major hindrance to the clinical efficacy for treated patients with gastrointestinal malignancies. Thus, a multitude of efforts have been made to combat and eradicate GCSCs within the tumor mass. Among diverse methods of targeting CSCs in gastrointestinal malignancies, immunotherapy represents a promising strategy. And the better understanding of GCSCs immunomodulation and immunoresistance mechanisms is beneficial to guide and design novel GCSCs-specific immunotherapies with enhanced immune response and clinical efficacy. In this review, we have gathered available and updated information to present an overview of the immunoevasion features harbored by cancer stem cells, and we focus on the description of immune escape strategies utilized by CSCs and microenvironmental regulations underlying CSCs immuno-suppression in the context of gastrointestinal malignancies. Importantly, this review offers deep insights into recent advances of CSC-targeting immunotherapeutic approaches in gastrointestinal cancers.

show abstract

S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3‐mediated programmed death‐ligand 1 expression in colorectal cancer

Cited by 12 publications

References 86 publications

HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation

HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation

Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy

Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

Contact Info

Product

Resources

About